There is a phase 3 randomized, open-label, multi-center study comparing the safety and efficacy of the BTK inhibitor, BGB-3111, and ibrutinib (NCT03053440); 75 subjects with MYD88-positive Waldenström macroglobulinemia will receive ibrutinib, and the other arm will receive BGB-3111 until progressive disease. The gene discussed is MYD88; the disease is Waldenstrom macroglobulinemia.